Swiss Rockets Welcomes Former Genentech Business Development Executive Thomas Zioncheck as Chief Strategy Officer

This appointment marks a major milestone in Swiss Rockets’ journey as an incubator and accelerator for breakthrough biopharmaceutical innovations. Dr. Zioncheck will lead business development efforts across all Swiss Rockets portfolio companies, drive pharma partnerships, and support the translation of innovative science into market-ready products. With his unparalleled network in Pharma and decades of expertise, he will play a pivotal role in bringing Swiss Rockets’ therapies to patients worldwide.

Dr. Vladimir Cmiljanovic, CEO of Swiss Rockets AG, said:
“We are thrilled to welcome Tom to our team. His track record at Genentech speaks for itself, he is among the very best in the industry. Having his experience, network, and strategic vision on board is a tremendous validation of our work and a powerful signal of what lies ahead for Swiss Rockets. This is a transformative step toward positioning our companies as leaders in biotech innovation.”

Dr. Thomas Zioncheck added:
“Swiss Rockets brings together an exciting and broad portfolio of promising science including programs in neurology, oncology, next-generation vaccines and dermatology. I am excited to help accelerate their vision, forge strong pharma partnerships, and ensure that these innovations find their way to patients. It is an honor to join such a dynamic and forward-looking team.”

Swiss Rockets’ appointment of Dr. Zioncheck underscores the company’s commitment to excellence and its ambition to shape the future of biotech. With his leadership in business development, Swiss Rockets is ideally positioned to secure world-class partnerships and bring its groundbreaking products to market.